<?xml version="1.0" encoding="UTF-8"?>
<!DOCTYPE article PUBLIC "-//NLM//DTD JATS (Z39.96) Journal Publishing DTD v1.3 20210610//EN" "JATS-journalpublishing1-3.dtd">
<article article-type="research-article" dtd-version="1.3" xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xml:lang="ru"><front><journal-meta><journal-id journal-id-type="publisher-id">biopreparat</journal-id><journal-title-group><journal-title xml:lang="ru">БИОпрепараты. Профилактика, диагностика, лечение</journal-title><trans-title-group xml:lang="en"><trans-title>Biological Products. Prevention, Diagnosis, Treatment</trans-title></trans-title-group></journal-title-group><issn pub-type="ppub">2221-996X</issn><issn pub-type="epub">2619-1156</issn><publisher><publisher-name>Scientific Centre for Expert Evaluation of Medicinal Products</publisher-name></publisher></journal-meta><article-meta><article-id custom-type="elpub" pub-id-type="custom">biopreparat-18</article-id><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="ru"><subject>ОБЗОРЫ</subject></subj-group><subj-group subj-group-type="section-heading" xml:lang="en"><subject>REVIEWS</subject></subj-group></article-categories><title-group><article-title>Биоаналоги - преимущества и перспективы</article-title><trans-title-group xml:lang="en"><trans-title>Biosimilars - advantages and prospects</trans-title></trans-title-group></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Лиджиева</surname><given-names>Алевтина Анатольевна.</given-names></name><name name-style="western" xml:lang="en"><surname>Lidzhiyeva</surname><given-names>A. A.</given-names></name></name-alternatives><email xlink:type="simple">saadq@yandex.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Смолярчук</surname><given-names>Елена Анатольевна</given-names></name><name name-style="western" xml:lang="en"><surname>Smolyarchuk</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib><contrib contrib-type="author" corresp="yes"><name-alternatives><name name-style="eastern" xml:lang="ru"><surname>Ельцова</surname><given-names>Елена Александровна.</given-names></name><name name-style="western" xml:lang="en"><surname>Eltsova</surname><given-names>E. A.</given-names></name></name-alternatives><email xlink:type="simple">noemail@neicon.ru</email><xref ref-type="aff" rid="aff-1"/></contrib></contrib-group><aff xml:lang="ru" id="aff-1"><institution>Государственное бюджетное образовательное учреждение высшего профессионального образования Первый Московский государственный медицинский университет им. И.М. Сеченова Министерства здравоохранения Российской Федерации</institution><country>Russian Federation</country></aff><pub-date pub-type="collection"><year>2015</year></pub-date><pub-date pub-type="epub"><day>20</day><month>02</month><year>2018</year></pub-date><volume>0</volume><issue>3</issue><fpage>21</fpage><lpage>24</lpage><permissions><copyright-statement>Copyright &amp;#x00A9; Лиджиева А.А., Смолярчук Е.А., Ельцова Е.А., 2018</copyright-statement><copyright-year>2018</copyright-year><copyright-holder xml:lang="ru">Лиджиева А.А., Смолярчук Е.А., Ельцова Е.А.</copyright-holder><copyright-holder xml:lang="en">Lidzhiyeva A.A., Smolyarchuk E.A., Eltsova E.A.</copyright-holder><license xml:lang="ru" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>Данная работа распространяется под лицензией Creative Commons Attribution 4.0.</license-p></license><license xml:lang="en" license-type="creative-commons-attribution" xlink:href="https://creativecommons.org/licenses/by/4.0/" xlink:type="simple"><license-p>This work is licensed under a Creative Commons Attribution 4.0 License.</license-p></license></permissions><self-uri xlink:href="https://www.biopreparations.ru/jour/article/view/18">https://www.biopreparations.ru/jour/article/view/18</self-uri><abstract><p>В настоящее время можно встреть два понятия биоаналог и биосимиляр. В целом это два взаимозаменяемых или синонимичных понятия, однако, правильнее будет говорить биоаналог. Согласно поправке от 22.12.2014 г. к Федеральному закону № 61 «Об обращении лекарственных средств». Так что такое биоаналог? Биоаналоги - это аналоги биофармацевтических лекарственных средств, с близкой, но не идентичной исходной молекулой. Они представляют собой современные лекарственные препараты на основе белков, полученных путем биологического синтеза в клетках дрожжей и бактерий. Впервые понятие «аналогичный биологический лекарственный продукт» было использовано в Директиве 2003/63/ЕС (ч. 2, абз. 4), дополнившей Директиву Европарламента и Евросоюза 2001/83/ Биотехнология - стремительно развивающаяся отрасль современного естествознания, которая находит все большее применение в различных сферах деятельности, и особенно в медицине. Все активнее разрабатываются и внедряются в медицинскую практику новые биофармацевтики - лекарственные средства, полученные с помощью современных биотехнологий. Развитие технологий в области производства «подобных» лекарственных средств набирает все большие обороты и ведет к снижению стоимости и доступности препаратов. На биотехнологические препараты сейчас возлагают основные надежды как на более доступные средства борьбы с наиболее опасными неинфекционными заболеваниями современности, такими как рак, рассеянный склероз, болезнь Альцгеймера, болезни накопления и др. В данном обзоре мы рассмотрим, чем же отличается оригинальное лекарственное вещество от дженерика, и что такое биоаналог. На сегодняшний день рынок биоаналогов активно развивается и имеет очень хорошие перспективы роста. По данным специалистов фармацевтической отрасли, в ближайшие годы биопрепараты составят не менее 50% всех лекарственных средств.</p></abstract><trans-abstract xml:lang="en"><p>Biotechnologie is a rapidly developing branch of modern science, which is increasingly used in various fields, especially in medicine. Increasingly developed and introduced into medical practice of new Biopharmaceuticals - medicines derived from modern biotechnology. The development of technology in the production of “similar” medicines is gaining momentum and leads to a reduction in the cost and availability of drugs. On biotech drugs now pinning major hopes on a more affordable means of combating the most dangerous non-communicable diseases of modernity, such as cancer, multiple sclerosis, Alzheimer’s disease, storage diseases, etc. In this review we will discuss what is the difference between the original medicinal substance from the generic, and what is the bioequivalent. To date, the biosimilars market is actively developing and has very good growth prospects. According to experts of the pharmaceutical industry in the coming years, the biologics will be at least 50% of all medicines.</p></trans-abstract><kwd-group xml:lang="ru"><kwd>biosimilars</kwd><kwd>generic drugs</kwd><kwd>biotechnology</kwd><kwd>pharmaceuticals</kwd><kwd>biotech drugs</kwd><kwd>биоаналоги</kwd><kwd>дженерики</kwd><kwd>биотехнология</kwd><kwd>лекарственные средства</kwd><kwd>биотехнологические препараты</kwd></kwd-group></article-meta></front><back><ref-list><title>References</title><ref id="cit1"><label>1</label><citation-alternatives><mixed-citation xml:lang="ru">The Commission of the European Communities (2003) Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. Official J Eur Union 2004; 47(L159): 46-94.</mixed-citation><mixed-citation xml:lang="en">The Commission of the European Communities (2003) Commission Directive 2003/63/EC of 25 June 2003 amending Directive 2001/83/EC of the European Parliament and of the Council on the Community code relating to medicinal products for human use. Official J Eur Union 2004; 47(L159): 46-94.</mixed-citation></citation-alternatives></ref><ref id="cit2"><label>2</label><citation-alternatives><mixed-citation xml:lang="ru">Misra A. Are biosimilars really generics? Expert Opin. Biol. Ther. 2010; 10(4): 489-4, Goldsmith D., Kuhlmann M., Covic A. Through the looking glass: the protein science of biosimilars. Clin Exp Nephrol. 2007;11: 1915.</mixed-citation><mixed-citation xml:lang="en">Misra A. Are biosimilars really generics? Expert Opin. Biol. Ther. 2010; 10(4): 489-4, Goldsmith D., Kuhlmann M., Covic A. Through the looking glass: the protein science of biosimilars. Clin Exp Nephrol. 2007;11: 1915.</mixed-citation></citation-alternatives></ref><ref id="cit3"><label>3</label><citation-alternatives><mixed-citation xml:lang="ru">Дугин И. На мировом фармрынке доминируют препараты. ФВ. Фармвестник. Available from: http://www.pharmvestnik.ru/publs/lenta/obzory/na-mirovom-farmrynke-dominirujut-biopreparaty.html#.U0wwBFV_tc0 (дата обращения 15.01.2015)</mixed-citation><mixed-citation xml:lang="en">Дугин И. На мировом фармрынке доминируют препараты. ФВ. Фармвестник. Available from: http://www.pharmvestnik.ru/publs/lenta/obzory/na-mirovom-farmrynke-dominirujut-biopreparaty.html#.U0wwBFV_tc0 (дата обращения 15.01.2015)</mixed-citation></citation-alternatives></ref><ref id="cit4"><label>4</label><citation-alternatives><mixed-citation xml:lang="ru">Сазыкин Ю.О., Орехов С.Н., Чакалева И.И. Биотехнология. Учебное пособие для студентов высших учебных заведений. 2008.</mixed-citation><mixed-citation xml:lang="en">Сазыкин Ю.О., Орехов С.Н., Чакалева И.И. Биотехнология. Учебное пособие для студентов высших учебных заведений. 2008.</mixed-citation></citation-alternatives></ref><ref id="cit5"><label>5</label><citation-alternatives><mixed-citation xml:lang="ru">Jenkins N., Murphy L., Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol Biotechnol. 2008; 39: 113-8.</mixed-citation><mixed-citation xml:lang="en">Jenkins N., Murphy L., Tyther R. Post-translational modifications of recombinant proteins: significance for biopharmaceuticals. Mol Biotechnol. 2008; 39: 113-8.</mixed-citation></citation-alternatives></ref><ref id="cit6"><label>6</label><citation-alternatives><mixed-citation xml:lang="ru">Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology derived Proteins as Drug Substance - Non Clinical and Clinical Issues containing Recombinant Human Erythropoietin, CHMP/94526/05, March 2006.</mixed-citation><mixed-citation xml:lang="en">Annex to Guideline on Similar Biological Medicinal Products Containing Biotechnology derived Proteins as Drug Substance - Non Clinical and Clinical Issues containing Recombinant Human Erythropoietin, CHMP/94526/05, March 2006.</mixed-citation></citation-alternatives></ref><ref id="cit7"><label>7</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Drug Substance - Non Clinical and Clinical Issues, EMEA/CHMP/BMWP/42832/05, February 2006.</mixed-citation><mixed-citation xml:lang="en">Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Drug Substance - Non Clinical and Clinical Issues, EMEA/CHMP/BMWP/42832/05, February 2006.</mixed-citation></citation-alternatives></ref><ref id="cit8"><label>8</label><citation-alternatives><mixed-citation xml:lang="ru">Committee for medicinal products for human use (CHMP) Available from: http://www.triskel.com/2%20Guideline%20biotech%20derived%20proteins.pdf (дата обращения 15.01.2015)</mixed-citation><mixed-citation xml:lang="en">Committee for medicinal products for human use (CHMP) Available from: http://www.triskel.com/2%20Guideline%20biotech%20derived%20proteins.pdf (дата обращения 15.01.2015)</mixed-citation></citation-alternatives></ref><ref id="cit9"><label>9</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on Similar Biological Medicinal Products containing biotechnology-derived proteins as active substance: quality issues (revision 1). EMA., Committee for Medicinal Products for Human Use, 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127960.pdf (дата обращения 14.04.2014).</mixed-citation><mixed-citation xml:lang="en">Guideline on Similar Biological Medicinal Products containing biotechnology-derived proteins as active substance: quality issues (revision 1). EMA., Committee for Medicinal Products for Human Use, 2012. Available from: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2012/05/WC500127960.pdf (дата обращения 14.04.2014).</mixed-citation></citation-alternatives></ref><ref id="cit10"><label>10</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues, CHMP/BMWP/403543/2010, May 2012.</mixed-citation><mixed-citation xml:lang="en">Guideline on similar biological medicinal products containing monoclonal antibodies - non-clinical and clinical issues, CHMP/BMWP/403543/2010, May 2012.</mixed-citation></citation-alternatives></ref><ref id="cit11"><label>11</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on similar biological medicinal products containing recombinant interferon alpha, CHMP/BMWP/102046/2006, October 2007.</mixed-citation><mixed-citation xml:lang="en">Guideline on similar biological medicinal products containing recombinant interferon alpha, CHMP/BMWP/102046/2006, October 2007.</mixed-citation></citation-alternatives></ref><ref id="cit12"><label>12</label><citation-alternatives><mixed-citation xml:lang="ru">IMS Health 2007 &amp; 2009, Evaluate Pharma, Sandoz analysis. С! ПРЕПАРАТЫ</mixed-citation><mixed-citation xml:lang="en">IMS Health 2007 &amp; 2009, Evaluate Pharma, Sandoz analysis. С! ПРЕПАРАТЫ</mixed-citation></citation-alternatives></ref><ref id="cit13"><label>13</label><citation-alternatives><mixed-citation xml:lang="ru">The European Parliament and the Council of the European Union (2004) Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official J Eur Union 2004; 47 (L136): 34-57.</mixed-citation><mixed-citation xml:lang="en">The European Parliament and the Council of the European Union (2004) Directive 2004/27/EC of the European Parliament and of the Council of 31 March 2004 amending Directive 2001/83/EC on the Community code relating to medicinal products for human use. Official J Eur Union 2004; 47 (L136): 34-57.</mixed-citation></citation-alternatives></ref><ref id="cit14"><label>14</label><citation-alternatives><mixed-citation xml:lang="ru">European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Drug Substance -Non Clinical and Clinical Issues, EMEA/CHMP/BMWP/42832/05, February 2006. Available from: www.ema.europa.eu/pdfs/human/biosimilar/4283205en Accessed Sept 2, 2010.</mixed-citation><mixed-citation xml:lang="en">European Medicines Agency. Guideline on Similar Biological Medicinal Products Containing Biotechnology-derived Proteins as Drug Substance -Non Clinical and Clinical Issues, EMEA/CHMP/BMWP/42832/05, February 2006. Available from: www.ema.europa.eu/pdfs/human/biosimilar/4283205en Accessed Sept 2, 2010.</mixed-citation></citation-alternatives></ref><ref id="cit15"><label>15</label><citation-alternatives><mixed-citation xml:lang="ru">Sahoo N., Choudhury, K., Manchikanti P. Manufacturing of biodrugs: need for harmonization in regulatory standards. Biodrugs 2009; 23: 217-29.</mixed-citation><mixed-citation xml:lang="en">Sahoo N., Choudhury, K., Manchikanti P. Manufacturing of biodrugs: need for harmonization in regulatory standards. Biodrugs 2009; 23: 217-29.</mixed-citation></citation-alternatives></ref><ref id="cit16"><label>16</label><citation-alternatives><mixed-citation xml:lang="ru">US Food and Drug Administration. Available from: www.fda.org. Accessed Sept 2, 2010.</mixed-citation><mixed-citation xml:lang="en">US Food and Drug Administration. Available from: www.fda.org. Accessed Sept 2, 2010.</mixed-citation></citation-alternatives></ref><ref id="cit17"><label>17</label><citation-alternatives><mixed-citation xml:lang="ru">Федерального закона от 24.12.2014 г. «О внесении изменений в Федеральный закон «Об обращении лекарственных средств» и в статью 333.32.1. части второй Налогового кодекса Российской Федерации».</mixed-citation><mixed-citation xml:lang="en">Федерального закона от 24.12.2014 г. «О внесении изменений в Федеральный закон «Об обращении лекарственных средств» и в статью 333.32.1. части второй Налогового кодекса Российской Федерации».</mixed-citation></citation-alternatives></ref><ref id="cit18"><label>18</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins. EMEA/CHMP/BMWP/14327/2006, December 2007.</mixed-citation><mixed-citation xml:lang="en">Guideline on Immunogenicity Assessment of Biotechnology-derived Therapeutic Proteins. EMEA/CHMP/BMWP/14327/2006, December 2007.</mixed-citation></citation-alternatives></ref><ref id="cit19"><label>19</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues EMEA/CHMP/BMWP/32775/2005_Rev., December 2012.</mixed-citation><mixed-citation xml:lang="en">Guideline on non-clinical and clinical development of similar biological medicinal products containing recombinant human insulin and insulin analogues EMEA/CHMP/BMWP/32775/2005_Rev., December 2012.</mixed-citation></citation-alternatives></ref><ref id="cit20"><label>20</label><citation-alternatives><mixed-citation xml:lang="ru">Об обращении лекарственных средств [Электронный ресурс]: Федеральный закон от 12.04.2010 N 61-ФЗ (ред. от 12.03.2014). Доступ из справ.-правовой системы «Консультант Плюс».</mixed-citation><mixed-citation xml:lang="en">Об обращении лекарственных средств [Электронный ресурс]: Федеральный закон от 12.04.2010 N 61-ФЗ (ред. от 12.03.2014). Доступ из справ.-правовой системы «Консультант Плюс».</mixed-citation></citation-alternatives></ref><ref id="cit21"><label>21</label><citation-alternatives><mixed-citation xml:lang="ru">Guideline on Similar Biological Medicinal Products, CPMP/437/04, October 2005.</mixed-citation><mixed-citation xml:lang="en">Guideline on Similar Biological Medicinal Products, CPMP/437/04, October 2005.</mixed-citation></citation-alternatives></ref><ref id="cit22"><label>22</label><citation-alternatives><mixed-citation xml:lang="ru">Солдатов А.А., Авдеева Ж.И., Алпатова Н.А., Медуницын Н.В., Киселевский М.В., Лысикова С.Л. и др. Проблемы регистрации биологических неоригинальных лекарственных препаратов. Биопрепараты 2014; (4); 25-36.</mixed-citation><mixed-citation xml:lang="en">Солдатов А.А., Авдеева Ж.И., Алпатова Н.А., Медуницын Н.В., Киселевский М.В., Лысикова С.Л. и др. Проблемы регистрации биологических неоригинальных лекарственных препаратов. Биопрепараты 2014; (4); 25-36.</mixed-citation></citation-alternatives></ref></ref-list><fn-group><fn fn-type="conflict"><p>The authors declare that there are no conflicts of interest present.</p></fn></fn-group></back></article>
